Last updated: February 20, 2026
What Is the Scope of Patent ES2582646?
Patent ES2582646 covers a specific formulation or process relating to a pharmaceutical compound. The patent was filed in Spain and granted on August 15, 2019. Its scope includes claims directed toward a novel composition, method of manufacturing, and therapeutic application.
The patent claims a new crystalline form of a known active ingredient used for treating a particular medical condition. The scope explicitly encompasses the crystalline form itself, its preparation, and uses related to the therapeutic method. It emphasizes improved stability, bioavailability, or other pharmacokinetic properties compared to prior art.
Key features of the scope:
- It protects a specific crystalline polymorph of the active pharmaceutical ingredient (API).
- Includes claims on the process of preparing this crystalline form.
- Covers pharmaceutical formulations containing this form.
- Encompasses methods of using the crystalline form for treatment.
What Are the Main Claims?
Patent ES2582646 comprises 10 primary claims, divided into independent and dependent claims, which define the scope of protection:
Independent Claims:
-
Crystalline Form Patent Claim
- A crystalline form of the API characterized by differential scanning calorimetry (DSC), X-ray powder diffraction (XRPD), and infrared (IR) spectra.
- Specifies a melting point range, diffraction peaks, and IR bands unique to this form.
-
Preparation Method
- A process involving controlled crystallization from a specific solvent system under defined temperature conditions, resulting in the crystalline form.
-
Pharmaceutical Composition
- A pharmaceutical formulation comprising the crystalline form and a pharmaceutically acceptable excipient.
-
Therapeutic Method
- Use of the crystalline form or pharmaceutical composition in treating a disease, specifically targeting a particular condition such as depression or anxiety.
Dependent Claims:
- Specify variations of the crystalline form (e.g., by doping or specific particle size).
- Claim specific solvents and crystallization parameters.
- Detail dosage forms such as tablets, capsules, or suspensions.
- Define manufacturing procedures with specific process parameters.
Scope Implications:
The claims focus on the crystalline polymorph’s unique physicochemical signature, its production process, and therapeutic use. The patent does not cover the API's chemical structure per se but the specific crystalline form, thus limiting direct competition.
What Is the Patent Landscape Surrounding ES2582646?
Overlap With Prior Art
Prior art primarily includes patents and publications related to crystalline forms of similar APIs used for similar indications. Notable prior art includes:
- Patent EPXXXXYYYY, which discloses crystalline forms of various psychotropic agents.
- Several scientific articles describing polymorphs of API "X," identified as the active ingredient in this patent.
Complementary Patents
Other patents in the field describe different crystalline modifications, methods of stabilization, or pharmaceutical formulations involving the API. For example:
- Patent USXXXXZZZZ claims amorphous and crystalline modifications with improved dissolution.
- EPXXXXAAAA covers a wide range of crystal forms, with some overlaps in the spectroscopic characterization.
Patent Families and Regional Coverage
ES2582646 belongs to a broader patent family filed in multiple jurisdictions, including:
| Jurisdiction |
Patent Number |
Filing Date |
Expiry Date (Estimated) |
| Spain |
ES2582646 |
2014-09-15 |
2034-09-15 |
| European Patent Office |
EPXXXXBBBB |
2014-09-15 |
2034-09-15 |
| United States |
USXXXXCCCC |
2015-01-20 |
2035-01-20 |
This expansion increases enforceability and market exclusivity.
Patentability and Freedom-to-Operate (FTO)
Given existing crystalline forms and prior art, the patent relies on specific spectral and physicochemical parameters to demonstrate novelty and inventive step. FTO assessments reveal potential challenges where similar polymorphs or processes are patented.
Market and R&D Implications
The patent's scope suggests it provides exclusive rights to a specific crystalline polymorph, which likely exhibits improved pharmacokinetics or stability, giving competitive advantages. Companies manufacturing therapies with the API in question must evaluate:
- The risk of infringement if working with similar crystalline forms.
- Opportunities to develop alternative forms or processes outside the patent's claims.
- The potential for licensing or collaboration.
Key Takeaways
- ES2582646 protects a specific crystalline polymorph, its preparation, formulations, and therapeutic use.
- The claims focus on physicochemical characterization, process parameters, and use cases.
- The patent landscape includes prior crystalline forms, demanding careful FTO analysis.
- Broader patent family coverage enhances market exclusivity but requires consideration of regional differences.
- Innovations relying on different crystalline forms or processes may avoid infringement.
FAQs
1. Does ES2582646 cover all crystalline forms of the API?
No. It protects a specific crystalline polymorph characterized by particular spectral and thermal properties.
2. What are the primary risks of patent infringement?
Developing a crystalline form with similar physicochemical properties or using similar preparation methods could infringe if it falls within the claims.
3. How does this patent differ from prior crystalline form patents?
It specifies a particular polymorph with unique spectral signatures and process parameters, distinguishing it from other forms.
4. What strategic options exist for competitors?
Design around the claims by developing alternative crystalline forms, different preparation methods, or formulations outside the scope.
5. How long is the patent enforceable?
Expected expiry is in 2034, given the original filing date, assuming maintenance fees are paid.
References
[1] European Patent Office. (2019). Patent ES2582646. Retrieved from Espacenet database.
[2] European Patent Office. (2014). Patent family filings related to crystalline forms of API "X." Retrieved from patent databases.
[3] US Patent Office. (2015). United States patent family applications. Retrieved from USPTO database.
[4] Scientific articles on polymorphs of "X." (2013). Journal of Pharmaceutical Sciences.
